Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Co-Diagnostics ( (CODX) ) has issued an announcement.
On March 9, 2026, Co-Diagnostics, Inc. received formal notice from Nasdaq that it had regained compliance with the $1.00 minimum bid price requirement and all other criteria for continued listing on The Nasdaq Capital Market. Trading in the company’s securities is set to resume on Nasdaq on March 11, 2026, while a one-year Discretionary Panel Monitor through March 9, 2027, means any renewed sub-$1.00 bid price stretch of 30 consecutive business days could trigger an immediate delisting determination without a new 180-day grace period.
Co-Diagnostics also disclosed preliminary, unaudited cash and cash equivalents of approximately $11.9 million as of December 31, 2025, subject to completion of year-end closing procedures and potential adjustment in its final financial statements. The combination of restored Nasdaq listing status and available cash levels provides investors with clearer visibility into the company’s short-term liquidity and ongoing compliance profile as it moves through 2026.
The most recent analyst rating on (CODX) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Co-Diagnostics stock, see the CODX Stock Forecast page.
Spark’s Take on CODX Stock
According to Spark, TipRanks’ AI Analyst, CODX is a Neutral.
The score is pressured primarily by poor financial performance (steep post-2021 revenue decline, sustained losses, and ongoing cash burn) and a bearish technical trend (price below key moving averages with negative MACD). Valuation is also constrained by negative earnings and no dividend support. Earnings-call initiatives and cost reductions provide only a modest offset, while the Nasdaq delisting risk is a significant additional negative factor.
To see Spark’s full report on CODX stock, click here.
More about Co-Diagnostics
Co-Diagnostics, Inc. is a molecular diagnostics company whose primary products focus on PCR-based tests designed to detect infectious diseases and other health conditions. The company is listed on The Nasdaq Capital Market, where maintaining compliance with listing standards, including minimum bid price requirements, is important to its access to public capital and visibility among investors.
Average Trading Volume: 62,025
Technical Sentiment Signal: Sell
Current Market Cap: $4.57M
See more data about CODX stock on TipRanks’ Stock Analysis page.